The biotin synthesis pathway in Mycobacteria tuberculosis is a new target for the development of anti-tuberculosis drugs
10.16438/j.0513-4870.2023-1040
- VernacularTitle:结核分枝杆菌生物素合成途径是抗结核菌药物开发的新靶点
- Author:
Ling-xi HUANG
;
Jian-ping XIE
- Publication Type:Research Article
- Keywords:
italic>Mycobacterium tuberculosis;
biotin;
biotin-dependent carboxylase;
biosynthesis;
first-line and second-line anti-tuberculosis drug
- From:
Acta Pharmaceutica Sinica
2024;58(3):503-510
- CountryChina
- Language:Chinese
-
Abstract:
italic>Mycobacterium tuberculosis, responsible for tuberculosis (TB), remains a major health problem worldwide and is one of the infectious diseases causing increased morbidity and mortality worldwide. Biotin, namely vitamin H, is an important cofactor necessary for fatty acid biosynthesis, gluconeogenesis and amino acid metabolism in organisms including Mycobacterium tuberculosis. Due to its inability to ingestion biotin from outside, Mycobacterium tuberculosis can only obtain biotin through biotin biosynthesis. Different from the classical BioC-BioH, BioI-BioW and non-classical BioZ pathways, Mycobacterium tuberculosis synthesized biotin by "BioC-BioH(2)" pathway in the early stage. This review focuses on the unique biotin synthesis pathway of Mycobacterium tuberculosis and its key genes, especially the response of this pathway and biotin-dependent carboxylase to tuberculosis first-and second-line drugs, as well as inhibitors and natural products targeting biotin synthesis.
